3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
10
Phase NA
7
Phase 2
6
Phase 3
2
Phase EARLY_PHASE1
1
Phase 4
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
169
Sarcoma
52
Breast
18
Thoracic
17
Dermatologic
12
Genitourinary
5
Head & Neck
4
Gastrointestinal
4
Other hematologic neoplasm
2
Gynecologic
2
Myeloid
1
Lymphoid
1
Endocrine
1
Conditions
Neuroendocrine Tumors
43
Carcinoma, Neuroendocrine
22
Small Cell Lung Carcinoma
13
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
11
Sarcoma
10
Lung Neoplasms
9
Thyroid Carcinoma, Anaplastic
7
Thyroid Cancer, Papillary
7
Stomach Neoplasms
7
Pheochromocytoma
7
Paraganglioma
7
Head and Neck Neoplasms
7
Gastro-enteropancreatic neuroendocrine tumor
7
Carcinoid Tumor
7
Thyroid Neoplasms
6
Neoplasm Metastasis
6
Colorectal Neoplasms
6
Ovarian Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Thyroid Diseases
4
Thoracic Neoplasms
4
Respiratory Tract Neoplasms
4
Respiratory Tract Diseases
4
Prostatic Neoplasms
4
Neuroblastoma
4
Neoplasms by Site
4
Multiple Endocrine Neoplasia Type 1
4
Lung Diseases
4
Interventions
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Brain Neoplasms
×
Endocrine
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA